Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, and Cancer Immunotherapy and Biomarkers.
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
ASTRIS: A Global Real-World Study of Osimertinib in >3000 Patients with <i>EGFR</i> T790M Positive Non-Small-Cell Lung Cancer
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Association between GWAS-identified lung adenocarcinoma susceptibility loci and<i>EGFR</i>mutations in never-smoking Asian women, and comparison with findings from Western populations
Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women
R331W Missense Mutation of Oncogene <i>YAP1</i> Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability
Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA)
<scp>G</scp>enetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia